Polycystic ovary syndrome management: a review of the possible amazing role of berberine.
Berberine
Insulin resistance
Nutraceutics
PCOS
VAT
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
15
04
2019
accepted:
23
01
2020
pubmed:
16
2
2020
medline:
9
7
2020
entrez:
16
2
2020
Statut:
ppublish
Résumé
The therapy of polycystic ovary syndrome (PCOS) is based on synthetic hormones associated with lifestyle changes, but these therapies cannot be taken continuously, especially by women who would like to become pregnant. Thus, nutraceutical compounds were investigated as possible agents for treatment of PCOS. Berberine is shown to be effective against insulin resistance and obesity, particularly against visceral adipose tissue (VAT). Because of these properties, researchers theorized that berberine could be effective in PCOS treatment. The aim of this narrative review was to assess the state of the art about the use of berberine in PCOS management. This review included 5 eligible studies. Despite the number of studies considered being low, the number of women studied is high (1078) and the results are interesting. Two authors find out that berberine induced a redistribution of adipose tissue, reducing VAT in the absence of weight loss and improved insulin sensitivity, quite like metformin. One author demonstrated that berberine improved the lipid pattern. Moreover, three authors demonstrated that berberine improved insulin resistance in theca cells with an improvement of the ovulation rate per cycle, so berberine is also effective on fertility and live birth rates. Finally, berberine is safe to use in premenopausal women who want to get pregnant and showed few side effects in all the cited studies. In conclusion, the use of berberine for PCOS is safe and promising, even if more studies are needed to create a consensus about the dosage of berberine useful for long-term therapy.
Identifiants
pubmed: 32060683
doi: 10.1007/s00404-020-05450-4
pii: 10.1007/s00404-020-05450-4
pmc: PMC7028834
doi:
Substances chimiques
Berberine
0I8Y3P32UF
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-60Références
Escobar-Morreale HF (2018) Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 14:270–284. https://doi.org/10.1038/nrendo.2018.24
doi: 10.1038/nrendo.2018.24
pubmed: 29569621
Wang Y, Fu X, Xu J et al (2016) Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome. Sci Rep. https://doi.org/10.1038/srep28089
doi: 10.1038/srep28089
pubmed: 28442790
pmcid: 5431370
Rondanelli M, Perna S, Faliva M et al (2014) Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena. Arch Gynecol Obstet 290:1079–1092. https://doi.org/10.1007/s00404-014-3433-z
doi: 10.1007/s00404-014-3433-z
pubmed: 25200687
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
Rocca ML, Venturella R, Mocciaro R et al (2015) Polycystic ovary syndrome: chemical pharmacotherapy. Expert Opin Pharmacother 16:1369–1393. https://doi.org/10.1517/14656566.2015.1047344
doi: 10.1517/14656566.2015.1047344
pubmed: 26001184
Ong M, Peng J, Jin X, Qu X (2017) Chinese herbal medicine for the optimal management of polycystic ovary syndrome. Am J Chin Med 45:405–422. https://doi.org/10.1142/S0192415X17500252
doi: 10.1142/S0192415X17500252
pubmed: 28359195
Liu D, Zhang Y, Liu Y et al (2018) Berberine modulates gut microbiota and reduces insulin resistance via the TLR4 signaling pathway. Exp Clin Endocrinol Diabetes. https://doi.org/10.1055/s-0043-125066
doi: 10.1055/s-0043-125066
pubmed: 30380573
Saleem F, Rizvi SW (2017) New therapeutic approaches in obesity and metabolic syndrome associated with polycystic ovary syndrome. Cureus 9:e1844. https://doi.org/10.7759/cureus.1844
doi: 10.7759/cureus.1844
pubmed: 29344438
pmcid: 5766352
Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9:407–416. https://doi.org/10.1016/j.cmet.2009.03.012
doi: 10.1016/j.cmet.2009.03.012
pubmed: 19416711
Catapano AL, Graham I, De Backer G et al (3058l) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999–3058l. https://doi.org/10.1093/eurheartj/ehw272
doi: 10.1093/eurheartj/ehw272
pubmed: 27567407
Yin J, Xing H, Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57:712–717. https://doi.org/10.1016/j.metabol.2008.01.013
doi: 10.1016/j.metabol.2008.01.013
pubmed: 18442638
pmcid: 2410097
Zhang Y, Li X, Zou D et al (2008) Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93:2559–2565. https://doi.org/10.1210/jc.2007-2404
doi: 10.1210/jc.2007-2404
pubmed: 18397984
Poli A, Barbagallo CM, Cicero AFG et al (2018) Nutraceuticals and functional foods for the control of plasma cholesterol levels An intersociety position paper. Pharmacol Res 134:51–60. https://doi.org/10.1016/j.phrs.2018.05.015
doi: 10.1016/j.phrs.2018.05.015
pubmed: 29859248
Di Pierro F, Bellone I, Rapacioli G, Putignano P (2015) Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes Targets Ther 8:89–96. https://doi.org/10.2147/DMSO.S78877
doi: 10.2147/DMSO.S78877
Di Pierro FF, Villanova N, Agostini F et al (2012) Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes Targets Ther 5:213. https://doi.org/10.2147/DMSO.S33718
doi: 10.2147/DMSO.S33718
Rooney S, Pendry B (2014) Phytotherapy for polycystic ovarian syndrome: a review of the literature and evaluation of practitioners’ experiences. J Herb Med 4:159–171. https://doi.org/10.1016/j.hermed.2014.05.001
doi: 10.1016/j.hermed.2014.05.001
Egger M, Smith GD, Altman DG (2001) Systematic reviews in health care: meta-analysis in context. BMJ Books, London
doi: 10.1002/9780470693926
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097
doi: 10.1371/journal.pmed.1000097
pubmed: 2707599
pmcid: 2707599
Wei W, Zhao H, Wang A et al (2012) A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol 166:99–105. https://doi.org/10.1530/EJE-11-0616
doi: 10.1530/EJE-11-0616
pubmed: 22019891
Li Y, Ma H, Zhang Y et al (2013) Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial. Trials 14:226. https://doi.org/10.1186/1745-6215-14-226
doi: 10.1186/1745-6215-14-226
pubmed: 23866924
pmcid: 3722087
Cicero AFG, Reggi A, Parini A et al (2014) Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia. High Blood Press Cardiovasc Prev 21:221–226. https://doi.org/10.1007/s40292-014-0052-5
doi: 10.1007/s40292-014-0052-5
pubmed: 24728953
An Y, Sun Z, Zhang Y et al (2014) The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf) 80:425–431. https://doi.org/10.1111/cen.12294
doi: 10.1111/cen.12294
Li Y, Kuang H, Shen W et al (2013) Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syndrome: study design of a double-blind randomised controlled trial. BMJ Open 3:e003934. https://doi.org/10.1136/bmjopen-2013-003934
doi: 10.1136/bmjopen-2013-003934
pubmed: 24282248
pmcid: 3845065
Wu X-K, Wang Y-Y, Liu J-P et al (2016) Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome. Fertil Steril 106:757–765.e1. https://doi.org/10.1016/j.fertnstert.2016.05.022
doi: 10.1016/j.fertnstert.2016.05.022
pubmed: 27336209
Orio F, Muscogiuri G, Palomba S et al (2013) Berberine improves reproductive features in obese Caucasian women with polycystic ovary syndrome independently of changes of insulin sensitivity. ESPEN J. https://doi.org/10.1016/j.clnme.2013.07.002
doi: 10.1016/j.clnme.2013.07.002